This silencing of DR4 is understood to be mediated by aberrant histone deacetylation [30], and treatment of medulloblastoma cell lines with the histone deacetylase (HDAC) inhibitor MS275 increased DR4 expression, via increased acetylation of H3 and H4 at its transcriptional start site, and enhanced TRAIL-induced apoptosis [30]. The gene discussed is TNFSF10; the disease is medulloblastoma.